Basel, February 18th, 2026 – FimmCyte AG (“FimmCyte”), a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and option-to-license agreement with Gedeon Richter Plc., a leading pharmaceutical company in women’s health.
FimmCyte was founded to take a differentiated path in women’s health therapeutics: applying immunotherapy precision to complex fibro-inflammatory diseases starting with endometriosis. Endometriosis treatment options remain limited to symptom management and surgery. Endometriosis affects 1 in 10 women globally and can have a profound impact on pain, fertility, and day-to-day functioning.
Under this collaboration, FimmCyte and Gedeon Richter will conduct joint research and development activities to accelerate FMC2 path towards the clinic and ultimately to patients.
